Message from Department Head

Welcome to the Department of Oncology at the University of Saskatchewan.

Established in 2024 as one of the university’s newer clinical departments, we are proud to be at the forefront of cancer care, research, and education in the province. Building on a longstanding foundation as a division within the College of Medicine, our transition to full departmental status reflects a growing commitment to uniting academic and clinical oncology under one umbrella, strengthening our ability to meet the evolving needs of cancer patients in Saskatchewan and beyond.
Our department is built on a strong foundation of collaboration with the Saskatchewan Cancer Agency, enabling us to integrate leading-edge clinical expertise with academic excellence. This partnership supports our shared mission: to deliver comprehensive, patient-centered care; to foster innovative, impactful research; and to train the next generation of oncology professionals committed to excellence and equity.

In this rapidly evolving field, we are committed to innovation, interdisciplinary collaboration, and continuous improvement. Our faculty, learners, and clinical partners work together to advance new approaches in cancer treatment and prevention, while promoting equity in care across Saskatchewan’s diverse communities.

Thank you for your interest in the Department of Oncology. Whether you are a prospective student, a healthcare provider, a researcher, or a member of the public, we welcome your engagement and invite you to learn more about how we are shaping the future of oncology care and research in Saskatchewan and beyond.

Dr. Shahid Ahmed, MD, PhD, FRCPC, FRCP (Edin), FACP
Interim Head Department of Oncology

About Us

The Department of Oncology within the College of Medicine operates as an independent unit. Its members are either employed by or contracted with the Saskatchewan Cancer Agency, and they work out of two primary locations: the Saskatoon Cancer Centre in Saskatoon and the Allan Blair Cancer Centre in Regina.  Our team is highly interdisciplinary comprising of physicians, physicists, epidemiologists, and research scientists who are based primarily in the Health Sciences Building at the University of Saskatchewan. Each member holds an academic appointment within the College of Medicine underscoring our dual commitment to clinical service and academic excellence. This distinctive composition enables a comprehensive approach to cancer care covering a wide range of specialties including medical oncology, radiation oncology, gynecologic oncology, and both general and malignant hematology. Our diverse expertise facilitates quality patient care along with creating a strong learning environment for training healthcare professionals. Additionally, our commitment to cancer research allows us to explore innovative treatments and contribute to advancements in oncology. Our mission is to provide patient-centered cancer services across Saskatchewan focusing on prevention, early detection, effective treatment, and innovative research. We are dedicated to the continual improvement of patient outcomes and the expansion of knowledge within the oncology field. Moreover, we are devoted to maintaining high standards in education and training for the next generation of healthcare providers. Through these efforts, we strive to enhance patient outcomes and advance the field of oncology.

Oncology Specialties

Medical Oncology is a sub-specialty of internal medicine dedicated to the diagnosis, treatment, and management of cancer. The field of Medical Oncology is constantly evolving, driven by research and the development of new treatment modalities. Recent advances include the expansion of targeted therapies and immunotherapies which aim to attack cancer cells while sparing healthy tissues, leading more precisely to more effective treatments. Precision medicine, where treatments are tailored to the genetic makeup of a cancer, is also becoming more common.

Medical oncologists are specialists who possess an in-depth understanding of the management of various types of cancer. Their expertise extends beyond the prescription of systemic therapy for a specific cancer. They are also skilled in assessing the overall health of patients, considering how patient-related and other factors may impact cancer treatment. This holistic approach is crucial for formulating the most effective treatment strategies while minimizing treatment-related toxicities.

The scope of work of a medical oncologist is broad, encompassing patient care from diagnosis through the course of the disease. This includes explaining the diagnosis and stage of cancer, discussing treatment options and their potential side effects, and facilitating supportive care and symptom management. Medical oncologists also play a leading role in the coordination of treatment plans, often acting as the primary point of contact among the various specialists involved in a patient's care. This coordination is essential for ensuring that treatments are administered effectively and that patients receive the support they need throughout their journey.

Moreover, medical oncologists are deeply involved in clinical research, testing new therapies, and contributing to the advancement of cancer treatments through clinical trials. This research is critical for discovering more personalized and effective treatment options.

Medical oncologists combine scientific knowledge with empathetic care playing a crucial role in the cancer care team. Their role is integral to the cancer care team offering hope and guidance to patients and their families during some of the most challenging times of their lives. Through their dedication to patient care, research, and education, medical oncologists continue to make significant contributions to the field of oncology improving outcomes and transforming the landscape of cancer treatment.

Medical Oncology Division Heads:

Regina – Dr. Muhammad Khan                     Saskatoon – Dr. Adnan Zaidi

Radiation Oncology is an important discipline within the field of cancer treatment focusing on the use of high-energy radiation to eradicate cancer cells and control cancer-related symptoms. This specialized branch of oncology plays an important role in the multidisciplinary approach to cancer care often complementing surgery, chemotherapy, and other treatments. Radiation oncology harnesses the power of various forms of radiation and charged particles to target cancer cells with precision, minimizing damage to surrounding healthy tissues.

Radiation oncologists are the medical doctors who specialize in treating cancer with radiation therapy. Their work involves designing and implementing treatment plans that use radiation to combat cancer effectively with a detailed assessment of the patient’s condition including the type and stage of cancer, its location, and the patient's overall health. The radiation oncologists collaborate closely with medical physicists and dosimetrists to plan and calculate the precise dose of radiation needed.

Radiation oncologists are actively involved in patient care before, during, and after radiation therapy. They work within a broader team of healthcare professionals, including radiation therapy technologists, nurses, medical physicists, and others ensuring that care is coordinated and holistic. This team approach facilitates a supportive environment for patients addressing not just the physical impact of cancer, but also the psychological and social aspects of the disease and its treatment.

Innovation and research are central to the field of radiation oncology, with ongoing advances in technology and treatment methods continually enhancing the precision, safety, and effectiveness of radiation therapy. Techniques such as intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy represent significant milestones in the ability to target tumors more accurately and with fewer side effects. Through their expertise and dedication, radiation oncologists play a vital role in the evolving landscape of cancer care, contributing to improved outcomes and quality of life for patients.

Radiation Oncology Division Heads:

Regina – Dr. Asim Amjad                               Saskatoon – Dr. Ali El-Gayed

Hematology is a specialized branch of medicine that focuses on the study, diagnosis, treatment, and prevention of diseases related to the blood and bone marrow, as well as the immunologic, hemostatic (blood clotting), and vascular systems. This complex field encompasses a wide range of benign disorders including anemia, bleeding disorders such as hemophilia, blood cancers like leukemia, lymphoma, and myeloma, and many other less common illnesses.

Hematologists are medical doctors who are specialized in diagnosing and treating blood disorders. Their expertise is not limited to cancers of the blood but extends to all blood-related conditions. Hematologists play a crucial role in patient care, from diagnosis to developing comprehensive treatment plans that may involve targeted medicine, blood transfusions, chemotherapy, bone marrow transplants, or cellular therapy. The work of a hematologist often intersects with various medical fields. This multidisciplinary approach ensures a holistic treatment plan tailored to the individual needs of each patient.

Hematologists are deeply involved in the longitudinal care of their patients, especially those with chronic conditions. They provide ongoing assessment and management to monitor the progress of the disease, adjust treatments as necessary, and address any emerging complications. Their role is not just confined to direct patient care; hematologists are also active in clinical research and teaching, contributing to the education of future physicians and the development of new therapies that continue to advance the field. Through clinical trials and laboratory research, they seek to better understand the underlying mechanisms of blood disorders aiming to improve diagnostic techniques, treatment modalities, and ultimately, patient outcomes.

The field of hematology is characterized by rapid advancements in technology and medicine. Hematologists, by applying the latest research findings to clinical practice, are constantly seeking better ways to care for their patients. Through their specialized knowledge and compassionate care, hematologists play a vital role in enhancing the health and well-being of those affected by blood disorders.

Stem cell transplants and CAR T-cell therapy are two innovative treatments in the field of hematology, offering new hope for patients with certain blood cancers and other severe blood-related diseases. Both stem cell transplants and CAR T-cell therapy are complex, high-risk treatments that require a multidisciplinary approach. Hematologists, in collaboration with a team of specialists, are integral to managing these therapies. They assess the suitability of patients for these treatments, oversee the collection and modification of cells, manage the administration of therapy, and monitor patients for adverse effects and response to treatment. Given the potential for severe side effects, such as cytokine release syndrome (CRS) in CAR T-cell therapy, hematologists' expertise in managing these complications is critical.

Through their dedication to patient care, excellence in education, and research, hematologists continue to make significant contributions to the field by teaching future healthcare providers, improving outcomes, and transforming the landscape of the treatment of both general and malignant hematology.

General Hematology Division Heads:

Regina – Dr. Ibraheem Othman                 Saskatoon – Dr. Kelsey Brose

Malignant Hematology Division Heads:

Regina – Dr. Ibraheem Othman                 Saskatoon – Dr. Waleed Sabry

Director of Stem Cell Transplant and Cellular Therapy Program:

Dr. Mohamed Elemary

Gynecologic Oncology is a specialized field of oncology that focuses on diagnosing, treating, and managing cancers that affect women's reproductive organs. This includes cancers of the ovary, uterus, cervix, vagina, and vulva. Given the complexity and variety of cancers within this specialty, gynecologic oncology requires a nuanced and highly specialized approach to patient care, integrating surgery, radiation therapy, chemotherapy, and targeted therapies to offer the best possible outcomes.

Gynecologic oncologists are specialists who have expertise in treating gynecologic cancers. Their training includes a residency in obstetrics and gynecology followed by a fellowship in gynecologic oncology, where they gain extensive experience in oncology, surgery, and the complexities of cancer treatment specific to female reproductive organs. This advanced training equips them with the skills to perform complex surgeries, including radical pelvic surgery and minimally invasive surgery such as laparoscopy or robotic-assisted surgery. They also have expertise in prescribing chemotherapy, targeted therapies, and immunotherapies, and collaborate with radiation oncologists when radiation therapy is indicated.

The role of gynecologic oncologists extends beyond the operating room and the clinic. They are deeply involved in the continuum of care for their patients from initial diagnosis through treatment and into survivorship or palliative care as needed. They work closely with a multidisciplinary team that includes radiation oncologists, pathologists, radiologists, nurse specialists, social workers, and other healthcare professionals to ensure a comprehensive and coordinated approach to treatment. This team collaboration is vital for addressing the complex needs of gynecologic cancer patients encompassing physical, emotional, and psychosocial support.

Gynecologic oncologists also play a crucial role in advancing the field through research and clinical trials. They are often involved in studies that explore new surgical techniques, novel chemotherapy drugs, targeted therapies, and innovative approaches to treatment that promise better outcomes. Their work contributes significantly to the evolving understanding of gynecologic cancers and the development of more effective, personalized treatment options.

Gynecologic Oncology Division Heads:

Regina – Dr. Maryam Al-Hayki                    Saskatoon – Dr. Vickie Martin

Under Construction

Oncology Areas

In Saskatchewan, Disease Site Groups play an important role in the comprehensive management of cancer patients across the province. These tumor groups consist of multidisciplinary teams of healthcare professionals specializing in specific cancer types, such as breast cancer, lung cancer, colorectal cancer, and many others. Led by expert oncologists, surgeons, pathologists, radiologists, and other specialists, these groups collaborate to ensure that patients receive personalized, evidence-based care tailored to their individual needs.

Each Disease Site Groups is dedicated to optimizing every aspect of cancer care, from diagnosis and treatment planning to survivorship and supportive care. Through regular tumor board meetings and case discussions, team members collectively review patient cases, evaluate treatment options, and develop customized care plans that prioritize patient outcomes and quality of life. This multidisciplinary approach fosters collaboration, innovation, and continuous improvement in cancer care delivery.

Furthermore, Disease Site Groups play a crucial role in advancing research and quality improvement initiatives in oncology. By participating in clinical trials, outcomes research, and quality improvement projects, these groups contribute to the development of new treatments, protocols, and best practices in cancer care. Ultimately, Disease Site Groups in Saskatchewan are instrumental in ensuring that cancer patients throughout the province receive the highest standard of care and support, empowering them to navigate their cancer journey with confidence and resilience.

Disease Site Group Directors:

Regina - Dr. Haji Chalchal, Medical Oncologist                     

Saskatoon - Dr. Vijayananda Kundapur, Radiation Oncologist

Medical physics integrates the principles and methodologies of physics with the field of medicine to enhance clinical practices and improve patient outcomes. This specialized area of physics applies its theories and methods to various aspects of healthcare, focusing particularly on the diagnosis, treatment, and monitoring of diseases.

Radiotherapy physics is a critical branch of medical physics that focuses on the application of physics principles in the design, implementation, and optimization of radiation therapy for cancer treatment. Radiotherapy physicists play an important role in ensuring that radiation treatments are not only effective but also as safe as possible for patient. Their expertise in dose calculation is vital for creating detailed treatment plans tailored to the unique anatomy of each patient. These calculations ensure that the prescribed radiation dose is delivered accurately to various depths and contours of the tumor. The physicists' understanding of radiobiology—the study of the biological effects of radiation—further aids in predicting and managing potential side effects in patients, thus enhancing the overall safety and efficacy of treatments.

Overall, the contributions of radiotherapy physicists are foundational to the success of radiation therapy in oncology. Their work ensures that treatment plans are scientifically sound, technologically advanced, and tailored to each patient's specific needs, ultimately contributing to better treatment outcomes.

Director of Medical Physics – Gavin Cranmer-Sargison

Epidemiology and Performance Measurement plays a crucial role in the field of cancer control by providing expertise in various areas such as treatment outcomes, epidemiological research, risk factor surveillance, evaluation, and cancer surveillance. By analyzing data and trends, this team helps to determine the effectiveness of cancer programs, assists in planning interventions, and works towards reducing the burden of cancer on the population of Saskatchewan.

One of the key contributions of Epidemiology and Performance Measurement is the production of the Saskatchewan Cancer Control Report. This report serves as a comprehensive status update on cancer surveillance for the province, offering insights into the current state of cancer incidence, prevalence, and mortality rates. Each edition of the report focuses on a special topic relevant to cancer control efforts, providing detailed information and analysis to inform decision-making and resource allocation.

Overall, the work of Epidemiology and Performance Measurement is instrumental in guiding evidence-based strategies for cancer control, ultimately contributing to better health outcomes and quality of life for the people of Saskatchewan. Through their expertise in data analysis, research, and reporting, this team plays a vital role in the ongoing effort to address cancer in the region.

The work of Epidemiology and Performance Measurement includes:
  • Cancer surveillance: collecting, analyzing, interpreting and communicating population-based cancer statistics in Saskatchewan
  • Cancer incidence and mortality projections
  • Screening programs: ongoing evaluation and monitoring of the screening programs for breast cancer, cervical cancer and colorectal cancer
  • Health economic analyses: cost-utility analysis with calculation of quality-adjusted life-years and cost-effectiveness analysis, among others
  • Program evaluation and performance measurement
  • Statistical and epidemiological research support for clinical studies
  • Survey development, analysis and interpretation
  • Investigation of potential cancer clusters
  • Review of clinical documentation for data abstraction, database development and entry
  • Quality assurance for agency data submissions to national and international cancer care organizations

Director of Epidemiology and Performance Measurement – Riaz Alvi

News

Healthy Future Sask (HFS) continues to be committed to meeting the project target of recruiting 7,000+ participants for this significant project. Recently, the HFS team attended the Sask Marathon Race Expo to connect with potential participants and share the value of cancer and chronic disease research.

The pre-race expo provided the platform for HFS team members Samantha Mapletoft (Provincial Manager HFS) and Bilal Bare (MPH Practicum student) to engage with attendees. They highlighted the value of the health research platform and emphasized the importance of the information provided by volunteer participants. The booth experience was impactful, with visitors sharing powerful personal stories of the way cancer and chronic disease has affected their lives.

As we head into summer, HFS will continue to attend community events to raise awareness and recruit participants to be part of this legacy project. We invite all SCA employees to help us reach our goal by signing up and sharing the word. Visit the HFS website for more information. Sign up today; together, we can make a difference in the health of our community.

Since 2012, Dr. Winston Lok has served as the Medical Advisor for the Screening Program for Cervical Cancer (SPCC). As the first family physician in this role, Dr. Lok has played a key role in several important changes within the program.

During Dr. Lok's tenure, the SPCC moved from the offices on Albert Street in Regina to the new facilities at Harbour Landing. This relocation has helped us expand and improve our services. Dr. Lok was integral in working with the Saskatchewan Registered Nurses Association to initiate training programs that enabled nurses across the province to perform advanced Pap testing. This training facilitated the establishment of pop-up Pap clinics, improving access to essential screening services.

Dr. Lok also co-authored the updated provincial cervical screening guidelines, helping to keep our practices updated. Alongside his SPCC responsibilities, Dr. Lok has actively participated in various health-care initiatives, including serving as the Family Practice Lead for the Regina area, as a member of the Continuing Care Provincial Committee, and on the MySaskHealthRecord committee.

Dr. Lok continues to work as a physician at Gardens Community Health Centre. As Dr. Lok steps down from his role as Medical Advisor, we thank him for his service and contributions to the SPCC and the Saskatchewan Cancer Agency.

We are also pleased to announce that Dr. Joanne Sivertson will assume the role of Medical Advisor for the SPCC in May 2024. We anticipate her contributions and leadership will greatly benefit the program.

Please join us in expressing gratitude to Dr. Lok for his service and in welcoming Dr. Sivertson to her new position.

On April 20, 2024, the University of Saskatchewan (USask) Senate voted unanimously to transition the Division of Oncology to the Department of Oncology. This marks the final step in a long road and is a significant milestone for the College of Medicine. This decision reflects oncology's integral role within the institutions clinical and academic spheres.

Oncology is an active clinical and academic division with an existing complement of more than 80 faculty between Saskatoon and Regina. These members have made significant contributions to the academic mission of the college and university for over 40 years through participation at all levels of medical education, continuing medical education and research. Their dedication to teaching has been consistently recognized through various awards, both within the college and across campus.

The decision to grant department status to oncology elevates the program and reinforces the invaluable contributions of faculty members to education and research. Additionally, it underscores the college's commitment to fully engaging all its faculty members. It strengthens oncology's involvement in the leadership and governance structures of the College of Medicine. Furthermore, this move aligns USask with most Canadian medical schools, which already have stand-alone oncology departments. By offering a dedicated oncology department, USask and the SCA can better attract and retain talent, further advancing its mission in medical education, cancer research, and patient care.

On Tuesday, March 5, 2024, Gynecologic Oncology hosted our third annual Precision Oncology Symposium. Led by Dr. Laura Hopkins, this meeting celebrated our prairie ovarian cancer research consortium, with scientists from Saskatchewan, Alberta and British Columbia joining our academic clinical team.

This year’s focus was on developing a unique and first-in-Canada program for ovarian cancer patients. This program will have its start as part of a research grant call, hosted by the Cancer Research Society. Our group received an invitation to submit a grant for $600,000 and we plan to enroll patients who are interested in a precision oncology approach to relapsed/progressive rare cancer sub-types. These cancers have been poorly studied and new information is badly needed.

This is unique because it will offer patients molecular sequencing and organoid development (an artificially grown mass of cells or tissue that resembles an organ) for functional drug repurposing screening. This will take the guess-work out of drug selection, providing clinicians with a list of ‘which drug is best’ (from our existing and approved drug options) as determined by testing the patient-derived organoid. Looking for drug targets in this ‘living tumour system’ has not been done anywhere in North America.

Saskatchewan’s CAR T team, comprised of dedicated health care providers at the SCA and SHA, was proud to deliver the revolutionary Chimeric Antigen Receptor T cell (CAR T) therapy to the very first patient in the province. We are thankful to now have this potentially life-saving treatment option available to eligible patients here in Saskatchewan.

Special thanks to the dedicated, hardworking and compassionate healthcare providers that make up the Stem Cell Transplant & Cellular Therapy team for everything you do to ensure our patients feel comfortable and supported throughout the transplant journey. The amazing work you do each and every day is saving lives and giving patients hope–patients like Cherylee Truitt, who was the first patient to receive CAR T treatment in the province. She is so appreciative and thankful for the support of her health care team. For more information on her journey so far, here is an excerpt from a recent SHA article:

Cherylee Truitt’s second birthday, as she calls it, has just passed, though she held off on the cake.

On May 17, she received a revolutionary therapy that is hoped to give her a second shot at life. Truitt has diffuse large B cell lymphoma, which made her a candidate for Chimeric Antigen Receptor T cell (CAR T) therapy, a treatment Saskatchewan began offering this spring. CAR T therapy uses a patient’s T cells which have essentially been supercharged so they can fight the patient’s cancer.

Until now, Saskatchewan patients referred for CAR T therapy travelled out of the province. Truitt is pleased the therapy is offered here, where her family, friends and her familiar care teams are within arm’s length.

“I’m never alone. They are just the best cheerleaders,” she said, noting her healthcare team members are just a call away anytime of the day or night. Truitt is grateful for the care she has received from so many people within and outside of the SHA and the SCA.

Read the full article.

On March 13, 2024, the Government of Saskatchewan proclaimed March as Multiple Myeloma Awareness Month. Thanks to Trevor Ives, a multiple myeloma patient, and SCA Hematologist, Dr. Julie Stakiw for their dedication to raising awareness about this rare cancer.

Saskatchewan patients with specific cancers can now receive an innovative type of immunotherapy closer to home. The Saskatchewan Cancer Agency (Cancer Agency), along with the Saskatchewan Health Authority (SHA), has launched the revolutionary Chimeric Antigen Receptor T-cell (CAR T) therapy to treat adult cancer patients with certain blood cancers and lymphomas in the province.

“We are pleased to now offer this revolutionary CAR T therapy in Saskatchewan, so that patients no longer need to travel out of province to take advantage of this potentially life-saving treatment,” Saskatchewan Cancer Agency President and CEO Deb Bulych said. “This exciting announcement would not be possible without the steadfast support from the Government of Saskatchewan, the Saskatchewan Health Authority and our health system partners.

The Government of Saskatchewan has provided initial funding of $2.128M to develop a commercial CAR T program and will provide an estimated $6.7M annually to operate the program and fund the cost of treatment for patients.  The CAR T therapy program, available in Saskatoon, includes collecting a patient’s T-cells (a type of immune system cell) from their blood and then engineering them with genetic material to recognize and attack cancer cells. Those cells are multiplied and then infused back into the patient where they can get to work destroying the cancer cells in their body.

Establishing a CAR T therapy in Saskatchewan has involved the expertise and commitment of the Saskatchewan Stem Cell Transplant and Cellular Therapy Program (SCTCTP) team at the Cancer Agency and the SHA, as well as partners in neurology, ICU and others.

The Saskatchewan Cancer Agency (SCA) is implementing a new tool for treating metastatic brain cancer, marking an important milestone in cancer care. This month, the SCA treated the first patient in Canada using the HyperArc stereotactic radiosurgery system.

HyperArc is a state-of-the-art and highly efficient radiosurgery treatment planning and delivery system. The precision of the HyperArc system provides high-quality treatments with reduced side effects. It is the latest technology to be rolled out through the SCA’s stereotactic radiosurgery program expansion.

“The Saskatchewan Cancer Agency strives to provide care of the highest quality to each patient who walks through our doors. Introducing HyperArc to our radiotherapy treatment options means that patients can receive world-class treatment closer to home,” said Dr. Jon Tonita, President and CEO of the Saskatchewan Cancer Agency.

The move to HyperArc is the latest step in the journey to expand the stereotactic radiosurgery program. The SCA has been offering stereotactic radiosurgery since 2016. The Varian HyperArc system was installed at the Allan Blair Cancer Centre (ABCC) earlier this year, thanks to $3.5-million in funding from the Ministry of Health.

“Our government is committed to funding leading-edge technology to help improve health outcomes for patients being treated at the Saskatchewan Cancer Agency. The benefit to Saskatchewan residents is priceless. Congratulations to the employees at the Agency for their hard work in implementing this new lifesaving technology,” said Minister of Health Paul Merriman.

Stereotactic radiosurgery delivers precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy brain tissue. “The field of radiosurgery is evolving rapidly, and I’m so proud of the SCA teams who worked over the past year to bring HyperArc to Saskatchewan. Providing patients with the most modern treatment available today is exciting and will lead to better outcomes and better quality of life for our patients with metastatic brain cancer,” said Dr. Gavin Cranmer-Sargison, Director of Medical Physics for the Saskatchewan Cancer Agency.

In 2020, the SCA treated 20 patients in Saskatoon using stereotactic radiosurgery. The recent program expansion at the ABCC in Regina will provide additional program capacity and treatment closer to home for many patients who live in southern Saskatchewan. In addition, the SCA will be rolling out HyperArc technology at the Saskatoon Cancer Centre later this year.

Events

Loading...

Contact

Interim Department Head
Dr. Shahid Ahmed, MD, PhD, FACP, FRCPC
Professor
20 Campus Drive
Saskatoon Cancer Centre
University of Saskatchewan
Saskatoon, SK  S7N 4H4

Phone: 306-655-2710
Fax: 306-655-0633

Administrative Contact

Eva Maslova
Phone: 306-655-2744